Heat Biologics

Heat Biologics Inc. is a US biotechnology company focused on the field of immunotherapy. Heat Biologics was founded by serial bio-tech entrepreneur Jeff Wolf and scientific cofounder Eckhard Podack, based upon Dr. Podack's novel work in the development of gp96 and other approaches to modulate the immune system, with multiple programs for indications in cancer, COVID-19, infectious disease, and others. The company is based in Morrisville, North Carolina.

For other uses, see Biological thermodynamics.
Heat Biologics
TypePublic
Nasdaq: HTBX
IndustryBiotechnology
Founded2008
HeadquartersMorrisville, North Carolina
Key people
Jeffrey Wolf
(Founder and CEO)
ProductsHS-110, HS-130, PTX-35 and COVID-19 program
Websitewww.heatbio.com

gp96

Heat Biologics’ proprietary gp96 platform leverages gp96’s role as a natural molecular warning system, engineered to secrete antigens bound to gp96, with broad applications in cancer treatment and vaccines for infectious diseases. Their lead product is in a Phase 2 trial for treatment of non-small cell lung cancer (NSCLC).

Pipeline products

HS-110

HS-110, also called viagenpumatucel-L, is in Phase II in NSCLC, in combination with cyclophosphamide. Another Phase I study is combining HS 110 with nivolumab and other checkpoint inhibitors.[1]

HS-130

HS-130 is in Phase I clinical trial for patients with solid tumors. HS-130 is an allogeneic (“off-the-shelf”) cell line engineered to express OX40 ligand fusion protein (OX40L-Fc). OX40 ligand is a key co-stimulator of T cells that augments antigen-specific CD8+ T cell responses.[2]

COVID-19 Vaccine

The company initiated a COVID-19 vaccine collaboration with the University of Miami in March 2020 using their gp96 platform which activates the human immune system to combat infectious diseases with the potential of generating long-term immune responses.[3]

PTX-35

PTX-35 is in Phase I clinical trial for patients with solid tumors. PTX-35 is a potential first-in-class T cell co-stimulator targeting TNFRSF25 (Death Receptor 3). Favorable safety profile was demonstrated in mice and non-human primates. PTX-35’s development plan focuses on cancer immunotherapy.[4]

Heat Biologics stock

Heat Biologics stock has been traded on the NASDAQ under ticker symbol HTBX since 24 July 2013.[5]

Main people

Heat Biologics' Chairman and CEO is Jeffrey Wolf, a serial Life Sciences entrepreneur who founded the company in 2008.

References
  1. Heat Biologics (2020-01-24). "A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease". {{cite journal}}: Cite journal requires |journal= (help)
  2. Heat Biologics (2020-09-14). "A Phase I, First-in-human, Dose-escalation Study to Evaluate the Safety and Immunologic Response After Administration of HS-130 in Combination With HS-110 (Viagenpumatucel-L) in Patients With Solid Tumors Refractory to Standard Care". {{cite journal}}: Cite journal requires |journal= (help)
  3. "Heat Biologics and University of Miami - gp96-Ig-S". GEN - Genetic Engineering and Biotechnology News. 2020-05-18. Retrieved 2021-01-12.
  4. "Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35". BioSpace. Retrieved 2021-01-12.
  5. "Heat Biologics, Inc. Announces Closing of Initial Public Offering of 2,500,000 Shares of Common Stock". Heatbio.com. July 29, 2013. Archived from the original on 2016-03-04. Retrieved 1 January 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.